Fig. 1. Impact of mevalonate pathway inhibitors and a γ-secretase inhibitor on cell viability.

a Mevalonate pathway inhibitors used in this study. HMG-CoA reductase is inhibited by lovastatin (Lov), farnesyl diphosphate synthase is inhibited by zoledronate (Zol), and geranylgeranyl diphosphate synthase is inhibited by DGBP. b Impact of prenyl synthase inhibitors on viability of U2OS osteosarcoma cells. Graphs display means and standard deviations of two independent experiments for each compound. c, d Cell viability of Molt-4 (c) and Jurkat (d) cells after 72 h of treatment with the γ-secretase inhibitor DAPT or the mevalonate pathway inhibitors lovastatin, zoledronate, or DGBP. Graphs display means and standard deviations of three independent experiments for each compound and cell line